ORMP vs. CLSD, BTAI, ANIX, ALLK, PMVP, OPTN, CUE, IOBT, DMAC, and ETON
Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Clearside Biomedical (CLSD), BioXcel Therapeutics (BTAI), Anixa Biosciences (ANIX), Allakos (ALLK), PMV Pharmaceuticals (PMVP), OptiNose (OPTN), Cue Biopharma (CUE), IO Biotech (IOBT), DiaMedica Therapeutics (DMAC), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical preparations" industry.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.
Oramed Pharmaceuticals has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500.
Clearside Biomedical has a consensus target price of $4.75, indicating a potential upside of 251.85%. Given Clearside Biomedical's higher probable upside, analysts plainly believe Clearside Biomedical is more favorable than Oramed Pharmaceuticals.
In the previous week, Clearside Biomedical had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 5 mentions for Clearside Biomedical and 2 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.59 beat Clearside Biomedical's score of -0.02 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Oramed Pharmaceuticals has higher earnings, but lower revenue than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 12.0% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 9.8% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Oramed Pharmaceuticals has a net margin of 0.00% compared to Clearside Biomedical's net margin of -394.91%. Clearside Biomedical's return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.
Clearside Biomedical received 39 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 67.17% of users gave Clearside Biomedical an outperform vote.
Summary
Oramed Pharmaceuticals beats Clearside Biomedical on 9 of the 17 factors compared between the two stocks.
Get Oramed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oramed Pharmaceuticals Competitors List
Related Companies and Tools
